<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970930</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0481</org_study_id>
    <nct_id>NCT01970930</nct_id>
  </id_info>
  <brief_title>Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV &amp; ET) Patients</brief_title>
  <official_title>Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to isolate and characterize stem cells of patients with
      Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not
      working the way they should be and why they seem to be sensitive to regulatory factors in the
      blood, such as clotting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it
      affects MPN stem cell function.

      Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN
      HSC/HPC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2, 2016</completion_date>
  <primary_completion_date type="Actual">June 2, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stem cell function</measure>
    <time_frame>at one time study visit</time_frame>
    <description>Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD34+ cells assays</measure>
    <time_frame>at one time study visit</time_frame>
    <description>Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">131</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>PV or ET</arm_group_label>
    <description>subject who has polycythemia vera or essential thrombocythemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood specimen</intervention_name>
    <description>4 green top tube 40 cc of blood draw</description>
    <arm_group_label>PV or ET</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CD34+ cells isolated from the peripheral blood Splenic CD34+ cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have polycythemia vera or essential thrombocythemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  polycythemia vera or essential thrombocythemia

          -  agree to give blood for study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue banking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

